Floatz logo

Losartan

Serious Mental Illness

Mclean HospitalSmall moleculePhase 4 / ApprovedDormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Serious Mental Illness cohort.

Asset / SponsorPhaseRating
Liraglutide
Anders Fink-Jensen, MD, DMSci
Phase 4BB
Opc-34712
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3BB
SIMVASTATIN
Mclean Hospital
Phase 4BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Bo Hu
Phase 2/3B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University Hospital, Bordeaux
Phase 3B

View all 15 →

Same molecule, other indications

Losartan is also rated in:

hypertensive disorderDormant
BBB
Indicative ·
76 / 100
View asset →
Cognitively Normal Older AdultsDormant
BB
Indicative ·
66 / 100
View asset →
Subjective Cognitive DeclineDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →